Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Blue Jet Healthcare shares rally 9% after Rs 800 crore QIP allotment
Blue Jet Healthcare shares rose sharply on Friday after the company completed its Rs 800 crore QIP, attracting marquee institutional investors, including multiple ICICI Prudential Mutual Fund schemes. The fund raise is expected to strengthen the company's balance sheet, support expansion plans, and boost long-term growth prospects while broadening its institutional shareholder base.
General insurers clock 16.7% premium growth
The general insurance sector saw a 16.7% premium income rise in June. Standalone health insurers led this growth with a 31% increase. First quarter collections for FY27 also climbed by 11.1%. Niva Bupa Health Insurance showed strong premium growth of 34% in June. ICICI Lombard General Insurance reported a 13.7% premium increase for the month.
Tech-Led global selloff, Fed rate fears weigh on Indian equities
Indian stock markets experienced their sharpest single-day drop in nearly a month, mirroring a global tech sell-off. The Nifty 50 and BSE Sensex both fell significantly, influenced by a strong US dollar and profit-taking after recent gains. While pharma and healthcare sectors showed resilience, most others, including metals and IT, declined. Market volatility increased, with analysts watching key support levels closely.
Volume buzzers: Unichem, Aegis Logistics soar up to 17%; ICICI Bank adds 3%
Unichem Laboratories, Aegis Logistics and ICICI Bank were among the volume toppers on the BSE and NSE on Thursday.
ICICI Lombard: AI Integration Lifts Growth Outlook — Buy, Sell or Hold? Read Motilal Oswal's Analysis
Leadership in motor insurance, accelerating momentum in retail health, expanding distribution capabilities, growing AI integration and a strong balance sheet remains ICICI Lombard's key growth drivers.
7 most valued firms' mcap eroded ₹1.25 trn last week, RIL took biggest hit
The combined market valuation of seven of the top-10 most-valued firms eroded by Rs 1.25 lakh crore last week, with Reliance Industries taking the biggest hit, in-line with a bearish trend in equities. Last week, the BSE benchmark Sensex declined 532.4 points, or 0.71 per cent, and the NSE Nifty dipped 181.05 points, or 0.76 per cent. "Persistent FII selling remained the key drag on market sentiment despite supportive developments such as cooling crude oil prices and a recovery in the rupee against the US dollar. Concerns regarding the pace of monsoon advancement also weighed on investor confidence," Santosh Meena, Head of Research at Swastika Investmart Ltd, said. From the top-10 pack, Reliance Industries, Bharti Airtel, Tata Consultancy Services (TCS), Bajaj Finance, Larsen & Toubro, Life Insurance Corporation of India (LIC) and Hindustan Unilever faced erosion from their valuation, while HDFC Bank, ICICI Bank, and State Bank of India were the gainers. The market valuation of ...
Stocks to buy today: Sudeep Pharma, Rubicon Research, ICICI Prudential AMC
Stocks to buy today: Aakash Shah of Choice Broking has recommended buying three stocks today - Rubicon Research, Sudeep Pharma, and ICICI Prudential Asset Management.
Indoco Remedies climbs after Baddi plant secures EU GMP certification; ICICI Prudential MF buys 1.47% stake
Indoco Remedies rose 4.04% to Rs 211.60 after the company said its oral solid dosage formulations facility at Baddi, Himachal Pradesh, received European Union Good Manufacturing Practice (EU GMP) certification from the German Health Authority (Berlin
Medtech exporter Poly Medicure bets on high-tech pivot and acquisitions to fend off macro headwinds
The medtech major expects its growth rate to more than double in FY27 as it pivots from low-cost consumables to high-value equipment to counter Chinese competition and rising input costs.
Aurobindo Pharma Q4 net profit, revenue rise on Europe growth; US sales decline
Shares of Aurobindo Pharma Ltd ended at ₹1,546.45, up by ₹28.55, or 1.88%, on the BSE.
Five Stocks To Buy: BSE, Infosys, ICICI Bank And More | May 19, 2026
Top picks include financial market infrastructure major BSE, IT giants Infosys and Coforge, pharmaceutical major Sun Pharma, and private sector lender ICICI Bank.
Gland Pharma Q4 profit surges 2x on strong US launches, CDMO growth; declares ₹20 dividend
The board recommended a final dividend of ₹20 per equity share for FY26, subject to shareholder approval. Shares of Gland Pharma Ltd ended at ₹1,861.00, down by ₹34.15, or 1.80%, on the BSE.